Identification and Preclinical Pharmacology of the γ-Secretase Modulator BMS-869780

Identification and Preclinical Pharmacology of the γ-Secretase Modulator BMS-869780

Alzheimer’s disease is the most prevalent cause of dementia and is associated with accumulation of amyloid-β peptide (Aβ), particularly the 42-amino acid Aβ1-42, in the brain. Aβ1-42 levels can be decreased by γ-secretase modulators (GSM), which are small molecules that modulate γ-secretase, an enzy...

Full description

Bibliographic Details
Main Authors: Jeremy H. Toyn, Lorin A. Thompson, Kimberley A. Lentz, Jere E. Meredith, Catherine R. Burton, Sethu Sankaranararyanan, Valerie Guss, Tracey Hall, Lawrence G. Iben, Carol M. Krause, Rudy Krause, Xu-Alan Lin, Maria Pierdomenico, Craig Polson, Alan S. Robertson, R. Rex Denton, James E. Grace, John Morrison, Joseph Raybon, Xiaoliang Zhuo, Kimberly Snow, Ramesh Padmanabha, Michele Agler, Kim Esposito, David Harden, Margaret Prack, Sam Varma, Victoria Wong, Yingjie Zhu, Tatyana Zvyaga, Samuel Gerritz, Lawrence R. Marcin, Mendi A. Higgins, Jianliang Shi, Cong Wei, Joseph L. Cantone, Dieter M. Drexler, John E. Macor, Richard E. Olson, Michael K. Ahlijanian, Charles F. Albright
Format: Article
Language:English
Published: Hindawi Limited 2014-01-01
Series:International Journal of Alzheimer's Disease
Online Access:http://dx.doi.org/10.1155/2014/431858

Internet

http://dx.doi.org/10.1155/2014/431858

Similar Items